Illumina Inc. (ILMN)
undefined
undefined%
At close: undefined
137.55
1.17%
After-hours Jan 03, 2025, 04:43 PM EST

Company Description

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis.

Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.

The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services.

Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies.

The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa.

The company was incorporated in 1998 and is based in San Diego, California.

Illumina Inc.
Illumina Inc. logo
Country United States
IPO Date Jul 28, 2000
Industry Medical - Diagnostics & Research
Sector Healthcare
Employees 10,590
CEO Jacob Thaysen Ph.D.

Contact Details

Address:
5200 Illumina Way
San Diego, California
United States
Website https://www.illumina.com

Stock Details

Ticker Symbol ILMN
Exchange NASDAQ
Fiscal Year February - January
Reporting Currency USD
CIK Code 0001110803
CUSIP Number 452327109
ISIN Number US4523271090
Employer ID 33-0804655
SIC Code 3826

Key Executives

Name Position
Jacob Thaysen Ph.D. Chief Executive Officer & Director
Jakob Wedel Chief Strategy & Corporate Development Officer and Chief Executive Officer Chief of Staff
Carissa L. Rollins Chief Information Officer
Dr. Steven Barnard Ph.D. Chief Technology Officer
Charles E. Dadswell Esq. Advisor
Kevin Carl Pegels Chief of Global Operations
Sallilyn Schwartz Vice President of Investor Relations
Scott Davies Interim General Counsel & Secretary
Scott Ericksen Vice President & Chief Accounting Officer
Stephanie Campos President

Latest SEC Filings

Date Type Title
Jan 02, 2025 4 Filing
Dec 09, 2024 4 Filing
Dec 06, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Dec 05, 2024 SC 13G Statement of acquisition of beneficial ownership b...
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 07, 2024 4 Filing
Nov 07, 2024 4 Filing
Nov 07, 2024 4 Filing
Nov 07, 2024 4 Filing
Nov 07, 2024 4 Filing